In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pralsetinib may interfere with the efficacy of hormonal contraceptives (includin···【more】
Release date:2026-01-16Recommended:167
Although severe adverse reactions to Pralsetinib (brand name: Gavreto) are relat···【more】
Release date:2026-01-16Recommended:145
Pralsetinib is indicated for the treatment of adult patients with specific types···【more】
Release date:2026-01-16Recommended:156
The efficacy of Pralsetinib was investigated in a multicenter, open-label, multi···【more】
Release date:2026-01-16Recommended:123
Pralsetinib is the sixth drug under Genentech that has obtained FDA approval for···【more】
Release date:2026-01-16Recommended:167
Please take pralsetinib strictly in accordance with the instructions of medical ···【more】
Release date:2026-01-16Recommended:138
Pralsetinib, also known as GAVRETO, is a targeted therapy medication administere···【more】
Release date:2026-01-16Recommended:169
Pralsetinib is a tyrosine kinase inhibitor administered via oral route.Which Pat···【more】
Release date:2026-01-16Recommended:114
Trabectedin (Yondelis) is a prescription medication indicated for the treatment ···【more】
Release date:2026-01-16Recommended:119
On December 1, 2020, South San Francisco, California – Genentech, a member of th···【more】
Release date:2026-01-15Recommended:136
On August 9, 2023, the U.S. Food and Drug Administration (FDA) approved pralseti···【more】
Release date:2026-01-15Recommended:116
Pralsetinib is indicated for the treatment of patients with metastatic (spread) ···【more】
Release date:2026-01-15Recommended:111